beta
Trial Radar IA
Lo studio clinico NCT03291470 per Osteoartrite degenerativa è attivo, non in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee Fase III 531 Randomizzato Doppio cieco Controllato con placebo Multicentrico

Attivo, non in arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT03291470 è uno studio interventistico di Fase III volto a esaminare il trattamento per Osteoartrite degenerativa, attualmente attivo, non in arruolamento. Avviato il 9 dicembre 2021, prevede di arruolare 531 partecipanti. Sotto la guida di Kolon TissueGene, Inc., dovrebbe concludersi entro il 6 marzo 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 30 dicembre 2025.
Sommario breve
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ult...Mostra di più
Descrizione dettagliata
This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the knee and determining disease modifying effects of TG-C. This study is intended for the treatment of patients with K&L Grade 2 and 3 osteoarthritis and OARSI JSN Grade 1 and 2. Assessments will be made on both the symptomatic effects of pain (VAS), function (WOMAC), and Quality of Life (SF-12) as well as ...Mostra di più
Titolo ufficiale

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee

Patologie
Osteoartrite degenerativa
Altri ID dello studio
  • TGC-15302
Numero NCT
Data di inizio (effettiva)
2021-12-09
Ultimo aggiornamento pubblicato
2025-12-30
Data di completamento (stimata)
2026-03-06
Arruolamento (previsto)
531
Tipo di studio
Interventistico
FASE
Fase III
Stato
Attivo, non in arruolamento
Parole chiave
knee
Scopo principale
Trattamento
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Quadruplo
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Comparatore attivoActive Treatment (TG-C)
TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
TG-C
2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
Comparatore placeboPlacebo Control (Normal Saline)
Normal saline, single 2 mL intraarticular injection
Controllo placebo
2 mL normal saline intraarticular injection
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Change in Knee Function as Assessed by the Western Ontario and McMaster Universities Index (WOMAC)
Assessment of change from baseline in target knee function using the WOMAC Osteoarthritis Index. The WOMAC is a proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee including pain, stiffness, and physical functioning of the joints. The response to the questions is in the form of a checked box associated with the response; None, Mild, Moderate, Severe and Extreme.
12 months
Change in Knee Pain as Assessed by VAS
Assessment of change from baseline in target knee pain using the Visual Analog Scale (VAS). The VAS is a method for the assessment of the intensity of pain. The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.
12 months
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
MRI Assessment of Target Knee
Assessment of knee organ tissues and structure by comparing change in MRI scoring using WORMS and partial MRI Osteoarthritis Knee Score (MOAKS)
12 months
PCS of the SF-12 Questionnaire
Evaluation of the change from baseline in physical component score (PCS) of the SF-12v2 questionnaire.
12 months
WOMAC Total Score
Evaluation of the efficacy of TG-C with regard to knee function via WOMAC total score
24 Months
Health Assessment Questionnaire Disability Index
Evaluation of the change from baseline in the disability index of the Health Assessment Questionnaire (HAQ-DI)
12 months
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
40 Years
Sessi idonei
Tutti
  • Aged 40 or older
  • BMI between 18.5 and 40
  • KL Grade 2 or 3 knee OA
  • OARSI Grade 1 or 2 medial JSN
  • Pain >= 40 on VAS scale
  • Written informed consent
  • Using birth control

  • Knee symptoms that result in difficulty or inability to walk
  • Knee effusion >2+
  • Has Grade 3 OARSI JSN
  • MRI exam indicates fracture or tumor
  • Has a positive result on RCR testing at screening
  • Has taken NSAIDS with 14 days of baseline
  • Has taken steroidal anti-inflammatory or biologic therapy medication within 2 months of baseline
  • Chronic (>21 days) narcotic use
  • Recent history (within 1 year) of drug or alcohol abuse
  • Pregnant or lactating
  • Has received injection to target knee within 2 months prior to study entry
  • History of various disorders of the knee including but not limited to rheumatoid arthritis, psoriatic arthritis, autoimmune disorder, chondrocalcinosis, gout, hemochromatosis, villonodular synovitis, or synovial chondromatosis
  • Severe hip osteoarthritis ipsilateral to the target knee
  • Ongoing infectious disease including but not limited to HIV, HTLV-1, VSV-G, HBV, or HCV.
  • Clinically significant congestive heart failure, hepatic disease, kidney disease, adrenal insufficiency, acromegaly, uncontrolled hyper- or hypothyroidism, or non-specified uncontrolled endocrine disorder.
  • Uncontrolled diabetes based on a HbA1c > 8% at screening.
  • Documented active malignancy within the last 5 years except for basal cell carcinoma, squamous cell carcinoma, and benign pigmented nevi.
Kolon TissueGene, Inc. logoKolon TissueGene, Inc.
Nessun dato di contatto
27 Centri dello studio in 1 paesi

Arizona

Nebojsa Skrepnik, Tucson, Arizona, 85712, United States

California

Steve Sitar, Anaheim, California, 92801, United States
Stuart Silverman, Beverly Hills, California, 90211, United States
Samy Metyas, Covina, California, 91722, United States
Bassil Aish, Huntington Beach, California, 92647, United States
Peter Hanson, La Mesa, California, 91942, United States
John Beckes, San Diego, California, 92120, United States

Florida

Miguel Trevino, Clearwater, Florida, 33756, United States
Jan Hommen, Doral, Florida, 33126, United States
Mira Baron, West Palm Beach, Florida, 33409, United States

Idaho

Richard Radnovich, Boise, Idaho, 83713, United States

Illinois

Thomas Schnitzer, Chicago, Illinois, 60611, United States

Michigan

Nathan Rimmke, Rochester Hills, Michigan, 48307, United States

Missouri

Larkin Wadsworth, St Louis, Missouri, 63141, United States

Nevada

Duane C Anderson, Las Vegas, Nevada, 89109, United States

New York

Igor Grosman, Brooklyn, New York, 11235, United States
Jonathan Samuels, New York, New York, 10016, United States

North Carolina

Minal Desai, Durham, North Carolina, 27704, United States
Jeremy Hoff, Wilmington, North Carolina, 28412, United States

Ohio

Priyesh Mehta, Dayton, Ohio, 45432, United States

South Carolina

Edward Tavel, Charleston, South Carolina, 29406, United States

Texas

Sefanit Gebretsadik, Dallas, Texas, 75230, United States
Manjoo Sharma, Lewisville, Texas, 75057, United States
Haresh Boghara, Red Oak, Texas, 75154, United States
Leonel Reyes, San Antonio, Texas, 78215, United States
Lisa Blair, San Antonio, Texas, 78229, United States

Washington

David Scott, Spokane, Washington, 99218, United States